Business Talk

FDA lays out new assessment framework for certain nitrosamines

Late last week, the FDA addressed developing knowledge – and concern – about nitrosamine drug substance related impurities (NDSRIs) in a final, immediately-in-effect guidance for industry. The guidance introduces a new approach and a host of tools for risk assessment of these recently discovered impurities. However, manufacturers face tight timelines for implementing them.

Quick background on nitrosamines in pharmaceutical products

Nitrosamines are a large and diverse class of chemicals, with more than 300 different structurally distinct species known today.

Fill out the form to read the full article.

Copy link
Powered by Social Snap